Further validation is required to provide guidance on how to differentiate between lorlatinib and alectinib for advanced ALK-p NSCLC and at what stage of the treatment sequence (first-line, second-line, etc.)lorlatinib will be the most beneficial to patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.